This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
India
Advinus Therapeutics is a Drug Discovery and Development services and collaborations company. They are currently focused on generating novel small molecule for indications in four therapeutic areas: Metabolic Diseases, Inflammatory Diseases, Pain/Neurodegenerative Diseases and Neglected Diseases of the developing world.
Project oriented multidisciplinary
Project oriented multidisciplinary
Aurigene Discovery Technologies Ltd is a drug discovery biotechnology company engaged in small-molecule and peptide drug discovery. The company specializes in oncology and inflammatory disease.
Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India. BIBCOL?s principal mission is to save the lives of millions of children from avoidable disability, through polio vaccination.
Biocon is a fully integrated healthcare company that delivers innovative biopharmaceutical solutions. Company manufactures generic active pharmaceutical ingredients (APIs) like Statins and Immunosuppressants that are sold in the developed markets of the United States and Europe. It also manufactures biosimilar Insulins, which are sold in India as branded formulations and in both bulk and formulation forms.
Biogenomics is focused on developing products using the Recombinant DNA technology. Company's product pipeline includes therapeutic biomolecules arising via recombinant proteins derived from microbial and mammalian cell culture based fermentation technologies.
Connexios Life Sciences Pvt Ltd is a drug discovery company focused on identifying novel targets and targeted small molecule therapeutics to address unmet needs in type 2 diabetes and metabolic diseases.
GangaGen, Inc. is a biotechnology company focused on the development of proprietary products for the prevention and treatment of bacterial infections, particularly infections that are resistant to antibiotics, through the application of contemporary molecular and clinical sciences. The company?s lead product is a recombinant protein, P128, that binds to and kills Staphylococcus, including methicillin-resistant strains of S. aureus (MRSA). This product is in late preclinical development.
Indus Biotech Private Limited is an innovative drug discovery company focused on on identifying and developing a new generation of drugs for Autoimmune, Oncology, CNS, Infectious and Lifestyle diseases. Company presently has discovery pipeline of 7 NCEs with strong activity in 13 therapeutic areas. These molecules are duly elucidated and patents are applied for under PCT/USPTO.
Intas is a leading, vertically integrated global pharmaceutical (formulation development, manufacturing and marketing) company based out of India.
It has grown to reach a revenue of over US$ 650 million in 2013 with a growth of ~30% CAGR over the last 5 years. Intas has its extensive presence in over 40 countries worldwide with robust sales, marketing and distribution infrastructure in highly regulated markets like North America, Europe, Latin America, South Africa, Australia & New Zealand.
In India only Intas has state-of-art EU-GMP approved microbial manufacturing site. Under co-development relationship, Intas's first biosimilar has received positive review from CHMP (formal MA to be received within 2013). Second biosimilar has completed Phase I in Canada and further clinical development for EU, US and Canada market.
Intas believes in creating strong pipeline and thus adhering it's strategy, Intas has gearing up for clinical development of two more biosimilars for regulated market like US and EU.
Development & manufacturing Technologies available with Intas:
? Microbial
? Pegylation
? Mammalian
? mAbs
Products launched in domestic and semi-regulated markets:
? GCSF
? EPO a
? INF Alfa-2b
? Peg-GCSF
? PTH
? Rituximab
? FSH
Additionally 9 biosimilars covering therapy segments of RA, fertility, non-cell small cancer, colon cancer, AMD are at various stages of development.
It has grown to reach a revenue of over US$ 650 million in 2013 with a growth of ~30% CAGR over the last 5 years. Intas has its extensive presence in over 40 countries worldwide with robust sales, marketing and distribution infrastructure in highly regulated markets like North America, Europe, Latin America, South Africa, Australia & New Zealand.
In India only Intas has state-of-art EU-GMP approved microbial manufacturing site. Under co-development relationship, Intas's first biosimilar has received positive review from CHMP (formal MA to be received within 2013). Second biosimilar has completed Phase I in Canada and further clinical development for EU, US and Canada market.
Intas believes in creating strong pipeline and thus adhering it's strategy, Intas has gearing up for clinical development of two more biosimilars for regulated market like US and EU.
Development & manufacturing Technologies available with Intas:
? Microbial
? Pegylation
? Mammalian
? mAbs
Products launched in domestic and semi-regulated markets:
? GCSF
? EPO a
? INF Alfa-2b
? Peg-GCSF
? PTH
? Rituximab
? FSH
Additionally 9 biosimilars covering therapy segments of RA, fertility, non-cell small cancer, colon cancer, AMD are at various stages of development.
Kasiak Research Private Limited is built on a vast experience and backed by a state-of-the-art R & D laboratory. They have developed industrial scale, clinical grade, stem cell expansion methods to produce affordable therapeutics. Their focus areas are Autologous and Allogeneic Human Stem Cells, Veterinary Stem Cells and Growth Factor Concentrate. They aim to develop products and provide Regenrative Cellutions to address unmet medical needs.
MM Biolabs Private Limited is a bio pharmaceutical R & D company by developing quality technology for producing API & intermediates and biopartnering.
Navya Biologicals develops and commercializes biopharmaceuticals & technologies to address healthcare needs. Their lead product NAVIH001 is a recombinant blood protein.